Statin use and infections in Veterans with cirrhosis

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 6, 2013, Pages 611-618

  Motzkus Feagans, C ^a   Pakyz, A L ^b   Ratliff, S M ^b   Bajaj, J S ^b,c   Lapane, K L ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; BACTEREMIA; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; INFECTION; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; LIVER CIRRHOSIS; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT IDENTIFICATION; PERITONITIS; PRIORITY JOURNAL; RISK REDUCTION; SEPTICEMIA; SKIN INFECTION; URINARY TRACT INFECTION; VETERAN;

EID: 84883053575     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12430     Document Type: Article

References (45)

1. Kim WR, Brown RS Jr, Terrault NA, El-Serag H,. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 36: 227-42.
2. Cazzaniga M, Dionigi E, Gobbo G, Fioretti A, Monti V, Salerno F,. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J Hepatol 2009; 51: 475-82.
3. Arvaniti V, D'Amico G, Fede G, et al,. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139: 1246-56, e1241-1245.
4. Bajaj JS, O'Leary JG, Reddy KR, et al,. Second infections independently increase mortality in hospitalized cirrhotic patients: the nacseld experience. Hepatology 2012; 56: 2328-35.
5. Tandon P, Garcia-Tsao G,. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008; 28: 26-42.
6. Khurana V, Caldito G, Ankem M,. Statins might reduce risk of renal cell carcinoma in humans: a case control study of 500,000 veterans. Urology 2008; 71: 118-22.
7. Friis S, Poulsen AH, Johnsen SP, et al,. Cancer risk among statin users: a population based cohort study. Int J Cancer 2005; 114: 643-7.
8. Chodick G, Heymann AD, Flash S, Kokia E, Shalev V,. Persistence with statins and incident cataract: a population-based historical cohort study. Ann Epidemiol 2010; 20: 136-42.
9. Fonseca AC, Resende R, Oliveira CR, Pereira CM,. Cholesterol and statins in Alzheimer's disease: current controversies. Exp Neurol 2010; 223: 282-93.
10. Janda S, Young A, Fitzgerald JM, Etminan M, Swiston J,. The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J Crit Care 2010; 25: 656.
11. Istvan ES, Deisenhofer J,. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001; 292: 1160-4.
12. Jain MK, Ridker PM,. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005; 4: 977-87.
13. Motzkus-Feagans C, Pakyz A, Polk R, Gambassi G, Lapane KL,. Statin use and the risk of Clostridium difficile in academic medical centres. Gut 2012; 61: 1538-42.
14. Yu W, Barnett PG, inventors. Reconciliation of DSS Encounter-Level National Data Extracts with the VA National Patient Care Database: Fiscal Year 2001. Menlo Park, CA: Health Economics Resource Center (HERC), 2001.
15. Murphy PA, Cowper DC, Seppala G, Stroupe KT, Hynes DM,. Veterans Health Administration inpatient and outpatient care data: an overview. Eff Clin Pract 2002; 5: E4.
16. Kamath PS, Wiesner RH, Malinchoc M, et al,. A model to protect survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
17. Lo Re V 3rd, Lim JK, Goetz MB, et al,. Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf 2011; 20: 689-99.
18. Nguyen GC, Segev DL, Thuluvath PJ,. Racial disparities in the management of hospitalized patients with cirrhosis and complications of portal hypertension: a national study. Hepatology 2007; 45: 1282-9.
19. Schneeweiss S, Robicsek A, Scranton R, Zuckerman D, Solomon DH,. Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. J Clin Epidemiol 2007; 60: 397-409.
20. Smith MW, Joseph GJ,. Pharmacy data in the VA health care system. Med Care Res Rev 2003; 60: 92S-123S.
21. Olson JC, Wendon JA, Kramer DJ, et al,. Intensive care of the patient with cirrhosis. Hepatology 2011; 54: 1864-72.
22. Goel GA, Deshpande A, Lopez R, Hall GS, van Duin D, Carey WD,. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol 2012; 10: 422-7.
23. Serste T, Merlot C, Francoz C, et al,. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010; 52: 1017-22.
24. Senzolo M, Cholongitas E, Burra P, et al,. Beta-blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int 2009; 29: 1189-93.
25. Romano PS, Roos LL, Jollis JG,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993; 46: 1075-9.
26. Rosenbaum PR, Rubin DB,. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
27. Rubin DB,. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 757-63.
28. Gagne JJ, Fireman B, Ryan PB, et al,. Design considerations in an active medical product monitoring system. Pharmacoepidemiol Drug Saf 2012; 21 (Suppl.): 32-40.
29. Tleyjeh IM, Kashour T, Hakim FA, et al,. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009; 169: 1658-67.
30. Kumar S, Grace N, Qamar A,. Statin therapy decreases the risk of hepatic decompensation in cirrhosis. Gastroenterology 2012; 142: S919-20.
31. Heeschen C, Hamm CW, Laufs U,. Platelet receptor inhibition in ischemic syndrome management (PRISM) investigators. Withdrawal of statins increases event rates in patient with acute coronary syndromes. Circulation 2002; 105: 1446-52.
32. van den Hoek HL, Bos WJ, de Boer A, van de Garde EM,. Statins and prevention of infections: systematic review and meta-analysis of data from large randomized placebo controlled trials. BMJ 2011; 343: d.7281.
33. Leung S, Pokharel R, Gong MN,. Statins and outcomes in patients with bloodstream infection: a propensity-matched analysis. Crit Care Med 2012; 40: 1064-71.
34. Bajaj JS, Ratliff SM, Heuman DM, Lapane KL,. Non-selective beta-blockers are not associated with serious infections in veterans with cirrhosis. Aliment Pharmacol Ther 2013; 38: 407-14.
35. Bajaj JS, Ratliff SM, Heuman DM, Lapane KL,. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharamacol Ther 2012; 36: 866-74.
36. Tsochatzis FA, Bosch J, Burroughs AK,. Prolonging survival in patients with cirrhosis. Gastroenterology. 2010; 139: 1813-5.
37. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA,. A pilot study using simvastatin in the treatment of non-alcoholic steatohepatitis. J Clin Gastroenterol 2009; 43: 990-4.
38. Stanca CM, Bach N, Allina J, Bodian C, Bodenheimer H Jr, Odin JA,. Atorvastatin does not improve liver biochemistries or Mayo risk score in primary biliary cirrhosis. Dig Dis Sci 2008; 53: 1988-93.
39. Tandra S, Vuppalanchi R,. Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med 2009; 11: 272-8.
40. Albrades JG, Abillos A, Banares R, et al,. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009; 136: 1651-8.
41. El-seraag HB, Johnson ML, Hachem C, Morgana RO,. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients. Gastroenterology 2009; 136: 1601-8.
42. Abu Rajab M, Kaplan MM,. Statins in primary biliary cirrhosis: are they safe? Dig Dis Sci 2010; 55: 2066-8.
43. Henderson LM, Patel S, Giordano TP, Green L, El-Serag HB,. Statin therapy and serum transaminases among a cohort of HCV-infected veterans. Dig Dis Sci 2010; 55: 190-5.
44. Murphy SL, Xu J, Kochanek KD,. Centers for Disease Control. Natl Vital Stat Rep 2012; 60: 4.
45. Fernandez J, Gustot T,. Management of bacterial infections in cirrhosis. J Hepatol 2012; 56 (Suppl. 1): S1-12.